For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
8 - 12 mg per m² of body surface area (BSA)
From 8 To 12 mg per m² of body surface area (BSA) once every day
12 mg/m²/day i.v. daily for 3 days in combination with cytarabine or 8 mg/m²/day i.v. daily for 5 days with/without combination.